 <h1>AccessPak for HIV PEP Basic Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>emtricitabine / tenofovir</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about emtricitabine / tenofovir. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name AccessPak for HIV PEP Basic.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to emtricitabine / tenofovir: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Emtricitabine/tenofovir disoproxil fumarate is not indicated for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy have not been established in patients co-infected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with HBV and HIV-1 and have discontinued emtricitabine / tenofovir; monitor hepatic function upon discontinuation of therapy. Emtricitabine / tenofovir disoproxil fumarate used for a PrEP indication is only for HIV-negative individuals; status confirmed immediately prior to initiating and periodically during use. Drug-resistant HIV-1 variants have been identified with use of emtricitabine / tenofovir disoproxil fumarate for a PrEP indication following undetected acute HIV-1 infection.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, emtricitabine / tenofovir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking emtricitabine / tenofovir:</p><p>
<i>More common</i>
</p><ul>
<li>Blisters under the skin</li>
<li>body aches or pain</li>
<li>chills</li>
<li>difficulty in breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>loss of voice</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>rash with flat lesions or small raised lesions on the skin</li>
<li>redness of the skin</li>
<li>runny or stuffy nose</li>
<li>sore throat</li>
<li>spots on your skin resembling a blister or pimple</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blindness or vision changes</li>
<li>burning of the face or mouth</li>
<li>burning, crawling, itching, numbness, painful, prickling, "pins and needles", or tingling feelings in the hands, arms, feet, or legs</li>
<li>chest pain</li>
<li>clumsiness or unsteadiness</li>
<li>stabbing pain</li>
<li>weakness in the hands or feet</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Agitation</li>
<li>bloating</li>
<li>bloody or cloudy urine</li>
<li>bone pain</li>
<li>change in how much or how often you urinate</li>
<li>confusion</li>
<li>constipation</li>
<li>cough</li>
<li>dark urine</li>
<li>decreased awareness or responsiveness</li>
<li>difficult or painful urination</li>
<li>difficulty in swallowing</li>
<li>fast heartbeat</li>
<li>fast, shallow breathing</li>
<li>general feeling of discomfort</li>
<li>increased thirst</li>
<li>indigestion</li>
<li>irritability</li>
<li>itching skin, hives, welts</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>lower back or side pain</li>
<li>muscle pain, cramp, or twitching</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>severe sleepiness</li>
<li>stomach pain</li>
<li>sudden decrease in the amount of urine</li>
<li>swelling of the face, fingers, hands, lower legs, or ankles</li>
<li>tightness in the chest</li>
<li>unusual drowsiness, dullness, or feeling of sluggishness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of emtricitabine / tenofovir may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Depression</li>
<li>diarrhea</li>
<li>nausea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>back pain</li>
<li>belching</li>
<li>difficulty in moving</li>
<li>heartburn</li>
<li>joint pain or swelling</li>
<li>lack or loss of strength</li>
<li>pain</li>
<li>passing of gas</li>
<li>stomach upset</li>
<li>sweating</li>
<li>trouble sleeping</li>
<li>vomiting</li>
<li>weight loss</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to emtricitabine / tenofovir: oral kit, oral tablet</i></p><h3>General</h3><p>In clinical trials, the most common side effects reported with emtricitabine and tenofovir alafenamide (with elvitegravir and cobicistat) were nausea, diarrhea, and headache.</p>
<p></p>
<p>Side effects have been reported for emtricitabine and/or tenofovir disoproxil fumarate (DF) when taken in combination with other antiretroviral agents.  The most common side effects reported in HIV-1-infected patients during a clinical study of efavirenz, emtricitabine, and tenofovir DF included diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.  In this trial, emtricitabine-tenofovir DF (with efavirenz) was used from weeks 96 to 144, replacing emtricitabine plus tenofovir DF (with efavirenz).</p>
<p></p>
<p>In HIV-1-uninfected individuals in HIV-1 preexposure prophylaxis trials, the most common side effect reported with emtricitabine-tenofovir alafenamide was diarrhea while the most common side effects reported with emtricitabine-tenofovir DF were headache, abdominal pain, and decreased weight.<sup>[Ref]</sup></p><h3>Other</h3><p>Emtricitabine-tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Fatigue</p>
<p>-Frequency not reported: Decreased high-density lipoprotein (HDL) cholesterol (fasted), increased triglycerides (fasted), increased total cholesterol to HDL ratio</p>
<p></p>
<p>Emtricitabine-tenofovir DF:</p>
<p>-Very common (10% or more): Increased fasting cholesterol (up to 22%)</p>
<p>-Common (1% to 10%): Fatigue, syphilis, secondary syphilis, decreased phosphorus, increased fasting triglycerides, weight decreased, increased alkaline phosphatase</p>
<p>-Frequency not reported: Decreased total cholesterol (fasted), decreased HDL cholesterol (fasted), decreased low-density lipoprotein (LDL) cholesterol (fasted), decreased triglycerides (fasted), increased total cholesterol to HDL ratio</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Fatigue, increased fasting total cholesterol, increased fasting LDL cholesterol</p>
<p>-Frequency not reported: Increased HDL cholesterol, increased triglycerides</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Asthenia</p>
<p>-Common (1% to 10%): Pain</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Pain, asthenia, increased triglycerides</p>
<p>-Common (1% to 10%): Chest pain, fever, weight loss</p>
<p>-Frequency not reported: Higher 1,25 vitamin D levels</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Increased weight, increased blood lipid levels<sup>[Ref]</sup></p><p>Increased fasting cholesterol (greater than 240 mg/dL: up to 22%), decreased phosphorus (2.5 to less than the lower limit of normal: up to 7%; less than 2 mg/dL: up to 10%), increased fasting triglycerides (greater than 750 mg/dL: up to 5%), and increased alkaline phosphatase (greater than 550 units/L: 1%) have been reported with emtricitabine-tenofovir DF.</p>
<p></p>
<p>In clinical trials, the following mean increases were reported in antiretroviral therapy-naive patients after using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat for 48 weeks: total cholesterol increased by 30 mg/dL, LDL cholesterol by 15 mg/dL, HDL cholesterol by 7 mg/dL, triglycerides by 29 mg/dL.  In clinical trials, the following mean increases were reported in patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat for 96 weeks: fasted total cholesterol increased by 31 and 14 mg/dL, fasted LDL cholesterol by 18 and 7 mg/dL, fasted HDL cholesterol by 7 and 4 mg/dL, fasted triglycerides by 31 and 13 mg/dL.</p>
<p></p>
<p>Increased fasting LDL cholesterol (greater than 190 mg/dL) has been reported in 8% and 4% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.  Increased fasting total cholesterol (greater than 300 mg/dL) has been reported in 3% and 2% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p>
<p></p>
<p>Asthenia has also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Emtricitabine-tenofovir DF:</p>
<p>-Very common (10% or more): Increased AST (up to 14%), increased ALT (up to 14%)</p>
<p>-Frequency not reported: Severe acute exacerbations of hepatitis B</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Increased AST</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Common (1% to 10%): Increased serum AST and/or increased serum ALT, hyperbilirubinemia</p>
<p>-Frequency not reported: Liver failure, liver decompensation, severe hepatomegaly with steatosis</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Common (1% to 10%): Increased transaminases (AST and/or ALT)</p>
<p>-Rare (less than 0.1%): Hepatic steatosis, hepatitis</p>
<p>-Frequency not reported: Severe hepatomegaly with steatosis</p>
<p>-Postmarketing reports: Increased liver enzymes (primarily AST, ALT, GGT)<sup>[Ref]</sup></p><p>Increased AST (1.25 to less than 2.5 times the upper limit of normal [1.25 to less than 2.5 x ULN]: up to 14%; greater than 2.6 x ULN: up to 5%) and ALT (1.25 to less than 2.5 x ULN: up to 14%; greater than 2.6 x ULN: up to 7%) have been reported with emtricitabine-tenofovir DF.</p>
<p></p>
<p>Increased AST (greater than 180 units/L) and ALT (greater than 215 units/L) have been reported in 3% and 2% of males using emtricitabine-tenofovir DF, respectively.  Increased AST (greater than 170 units/L) and ALT (greater than 170 units/L) have been reported in 3% and 2% of females using emtricitabine-tenofovir DF, respectively.</p>
<p></p>
<p>Increased AST (greater than 5 x ULN) has been reported in 2% and 2% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p>
<p></p>
<p>Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of this drug and were associated with liver failure and liver decompensation in some emtricitabine-treated patients.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p>
<p></p>
<p>Hepatic steatosis and hepatitis have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased neutrophils (1000 to 1300/mm3: up to 13%; less than 750/mm3: up to 5%) and hemoglobin (8.5 to 10 mg/dL: 4%; less than 9.4 mg/dL: up to 2%) have been reported with emtricitabine-tenofovir DF.</p>
<p></p>
<p>Anemia was common in pediatric patients using emtricitabine.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir DF:</p>
<p>-Very common (10% or more): Decreased neutrophils (up to 13%)</p>
<p>-Common (1% to 10%): Decreased hemoglobin</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Common (1% to 10%): Neutropenia</p>
<p>-Uncommon (0.1% to 1%): Anemia</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Common (1% to 10%): Decreased neutrophils<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Emtricitabine-tenofovir DF:</p>
<p>-Very common (10% or more): Pharyngitis (up to 13%)</p>
<p>-Common (1% to 10%): Sinusitis, upper respiratory tract infections, nasopharyngitis</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Rhinitis, increased cough</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Common (1% to 10%): Pneumonia</p>
<p>-Postmarketing reports: Dyspnea<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Increased serum amylase (greater than 175 units/L) has been reported in up to 8% of patients using emtricitabine-tenofovir DF.</p>
<p></p>
<p>In clinical trials, nausea was the most common side effect reported in antiretroviral therapy-naive HIV-1-infected patients using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat.</p>
<p></p>
<p>Increased amylase (greater than 2 x ULN) has been reported in 2% and 4% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p>
<p></p>
<p>Pancreatitis, abdominal pain, and increased amylase have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Diarrhea, nausea, abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal discomfort)</p>
<p></p>
<p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Diarrhea, nausea, increased serum amylase, abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal discomfort), vomiting</p>
<p>-Frequency not reported: Flatulence</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Very common (10% or more): Nausea</p>
<p>-Common (1% to 10%): Diarrhea, vomiting, abdominal pain, flatulence, increased amylase</p>
<p>-Uncommon (0.1% to 1%): Dyspepsia</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Diarrhea, nausea, abdominal pain</p>
<p>-Common (1% to 10%): Increased amylase (including increased pancreatic amylase), increased serum lipase, vomiting, dyspepsia</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Diarrhea, vomiting, nausea</p>
<p>-Common (1% to 10%): Abdominal pain, abdominal distension, flatulence, dyspepsia, increased serum amylase</p>
<p>-Uncommon (0.1% to 1%): Pancreatitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>In clinical trials of HIV-1-uninfected individuals, decreased BMD was reported.  During treatment with emtricitabine-tenofovir DF, 13% of patients lost at least 5% of BMD at the spine.</p>
<p></p>
<p>Increased creatine kinase (males: greater than 990 units/L; females: greater than 845 units/L) has been reported in up to 9% of patients using emtricitabine-tenofovir DF.</p>
<p></p>
<p>Increased creatine kinase (at least 10 x ULN) has been reported in 9% and 7% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p>
<p></p>
<p>In virologically-suppressed tenofovir DF-treated patients who switched to emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean BMD increased between baseline and week 48; decreased BMD was also reported.</p>
<p></p>
<p>Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.</p>
<p></p>
<p>Rhabdomyolysis, muscular weakness, and myopathy have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Decreased bone mineral density (BMD)</p>
<p>-Frequency not reported: Increased BMD</p>
<p></p>
<p>Emtricitabine-tenofovir DF:</p>
<p>-Very common (10% or more): Decreased BMD</p>
<p>-Common (1% to 10%): Increased creatine kinase, bone fractures, back pain</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Very common (10% or more): Decreased BMD</p>
<p>-Common (1% to 10%): Increased creatine kinase</p>
<p>-Uncommon (0.1% to 1%): Arthralgia</p>
<p>-Frequency not reported: Increased biochemical markers of bone metabolism, increased BMD, fractures (excluding fingers and toes)</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Increased creatine kinase</p>
<p>-Common (1% to 10%): Myalgia, arthralgia</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Increased creatine kinase</p>
<p>-Common (1% to 10%): Myalgia, arthralgia, back pain</p>
<p>-Uncommon (0.1% to 1%): Rhabdomyolysis, muscular weakness</p>
<p>-Rare (less than 0.1%): Myopathy</p>
<p>-Frequency not reported: Decreased BMD, increased biochemical markers of bone metabolism</p>
<p>-Postmarketing reports: Osteomalacia (manifested as bone pain and which may contribute to fractures)</p>
<p></p>
<p>Combination antiretroviral therapy:</p>
<p>-Frequency not reported: Osteonecrosis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hyperglycemia (greater than 250 mg/dL) has been reported in up to 2% of patients using emtricitabine-tenofovir DF.</p>
<p></p>
<p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p>
<p></p>
<p>Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.</p>
<p></p>
<p>Hypokalemia, lactic acidosis, and hypophosphatemia have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Hyperglycemia</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Common (1% to 10%): Hyperglycemia, hypertriglyceridemia, increased or decreased serum glucose</p>
<p>-Frequency not reported: Lactic acidosis</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Hypophosphatemia</p>
<p>-Common (1% to 10%): Anorexia, increased serum glucose</p>
<p>-Uncommon (0.1% to 1%): Hypokalemia</p>
<p>-Rare (less than 0.1%): Lactic acidosis</p>
<p></p>
<p>Antiretroviral therapy:</p>
<p>-Frequency not reported: Redistribution of body fat (lipodystrophy), increased glucose levels<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Depression, insomnia, abnormal dreams, anxiety</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Abnormal dreams</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Insomnia, abnormal dreams</p>
<p>-Common (1% to 10%): Depressive disorders</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Depression</p>
<p>-Common (1% to 10%): Insomnia, anxiety<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Emtricitabine-tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Headache</p>
<p></p>
<p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Dizziness, headache</p>
<p>-Frequency not reported: Somnolence</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Headache, dizziness</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Dizziness, headache</p>
<p>-Common (1% to 10%): Neuropathy/peripheral neuritis, paresthesia</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Dizziness, headache</p>
<p>-Common (1% to 10%): Peripheral neuropathy (including neuropathy, peripheral neuritis)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Rash event (including rash, maculopapular rash, exfoliative rash, generalized rash, macular rash, pruritic rash, vesicular rash)</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Rash</p>
<p>-Uncommon (0.1% to 1%): Pruritus</p>
<p></p>
<p>Emtricitabine:</p>
<p>-Very common (10% or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, allergic reaction)</p>
<p>-Common (1% to 10%): Skin discoloration (palmar-plantar hyperpigmentation)</p>
<p>-Frequency not reported: Lipodystrophy</p>
<p>-Postmarketing reports: Angioedema</p>
<p></p>
<p>Tenofovir alafenamide-containing products:</p>
<p>-Postmarketing reports: Angioedema, urticaria, rash</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Very common (10% or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash)</p>
<p>-Common (1% to 10%): Sweating</p>
<p>-Uncommon (0.1% to 1%): Lipodystrophy</p>
<p>-Rare (less than 0.1%): Angioedema<sup>[Ref]</sup></p><p>Skin discoloration (hyperpigmentation) was very common in pediatric patients using emtricitabine.</p>
<p></p>
<p>Rash has also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Renal</h3><p>Increased creatinine (1.1 to 1.3 x ULN: up to 2%; greater than 1.4 x ULN: less than 1%) has been reported with emtricitabine-tenofovir DF.</p>
<p></p>
<p>In 2 trials in antiretroviral therapy-naive HIV-1-infected patients (median estimated glomerular filtration rate [eGFR] 115 mL/min at baseline) using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine increased by 0.1 mg/dL from baseline to week 48; median UPCR was 44 mg/g at baseline and at week 48.  In a trial in virologically-suppressed tenofovir DF-treated patients (mean eGFR 112 mL/min at baseline) who switched to emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine was similar to baseline; median UPCR was 61 mg/g at baseline and 46 mg/g at week 48.  In a trial in renal dysfunction patients (baseline eGFR 30 to 69 mL/min) using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine was 1.5 mg/dL at baseline and week 24; median UPCR was 161 mg/g at baseline and 93 mg/g at week 24.</p>
<p></p>
<p>Proximal renal tubulopathy generally resolved or improved after tenofovir DF was stopped; however, decreased CrCl did not completely resolve in some HIV-1-infected patients after stopping the drug.  Rhabdomyolysis, osteomalacia, bone abnormalities (infrequently contributing to fractures), hypokalemia, muscular weakness, myopathy, and hypophosphatemia may occur as a result of proximal renal tubulopathy.</p>
<p></p>
<p>Renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, nephrogenic diabetes insipidus, and acute tubular necrosis have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir alafenamide:</p>
<p>-Uncommon (0.1% to 1%): Increased urine protein-to-creatinine ratio (UPCR)</p>
<p>-Frequency not reported: Decreased serum creatinine, increased estimated glomerular filtration rate (eGFR)</p>
<p></p>
<p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Increased creatinine, increased UPCR</p>
<p>-Frequency not reported: Decreased eGFR</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Frequency not reported: Increased serum creatinine, decreased UPCR, worsening renal function</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Uncommon (0.1% to 1%): Increased creatinine, proximal renal tubulopathy (including Fanconi syndrome)</p>
<p>-Rare (less than 0.1%): Renal failure (acute and chronic), acute tubular necrosis, nephrogenic diabetes insipidus</p>
<p>-Frequency not reported: New onset or worsening renal impairment</p>
<p>-Postmarketing reports: Renal insufficiency, interstitial nephritis (including acute cases)</p>
<p></p>
<p>Tenofovir prodrugs:</p>
<p>-Frequency not reported: Renal impairment (including renal failure, Fanconi syndrome)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Emtricitabine-tenofovir DF:</p>
<p>-Common (1% to 10%): Proteinuria, urethritis, urinary tract infection, hematuria, genital ulceration, anogenital warts</p>
<p>-Uncommon (0.1% to 1%): Glycosuria</p>
<p></p>
<p>Emtricitabine plus tenofovir alafenamide:</p>
<p>-Common (1% to 10%): Hematuria</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Common (1% to 10%): Glycosuria, hematuria</p>
<p>-Uncommon (0.1% to 1%): Proteinuria</p>
<p>-Postmarketing reports: Polyuria<sup>[Ref]</sup></p><p>Hematuria (greater than 75 RBC/high power field: up to 3%) and glycosuria (3+ or greater: less than 1%) have been reported with emtricitabine-tenofovir DF.</p>
<p></p>
<p>Hematuria (greater than 75 RBC/high power field) has been reported in 3% and 3% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p>
<p></p>
<p>Proteinuria has also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Emtricitabine-tenofovir DF:</p>
<p>-Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)</p><h3>Hypersensitivity</h3><p>Emtricitabine:</p>
<p>-Common (1% to 10%): Allergic reaction</p>
<p></p>
<p>Tenofovir DF:</p>
<p>-Postmarketing reports: Allergic reaction (including angioedema)<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Tenofovir DF:</p>
<p>-Frequency not reported: Higher serum parathyroid hormone levels<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Truvada (emtricitabine-tenofovir)." Gilead Sciences, Foster City, CA. </p><p id="ref_4">4. "Product Information. Descovy (emtricitabine-tenofovir)." Gilead Sciences, Foster City, CA. </p><p id="ref_5">5. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2018, May 30]):</p><p id="ref_6">6. Baeten JM,  Donnell D,  Ndase P, et al. "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women." N Engl J Med 367 (2012): 399-410</p><p id="ref_7">7. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_8">8. Paxton LA,  Hope T,  Jaffe HW "Pre-exposure prophylaxis for HIV infection: what if it works?" Lancet 370 (2007): 89-93</p><p id="ref_9">9. de Perio MA,  Gomez FJ,  Frame PT,  Fichtenbaum CJ "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS 21 (2007): 2252-3</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Truvada vs Descovy: How do they compare for HIV and PrEP?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about AccessPak for HIV PEP Basic (emtricitabine / tenofovir)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antiviral combinations</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Truvada</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
<li>Pre-Exposure Prophylaxis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to emtricitabine / tenofovir: oral kit, oral tablet</i></p><h3>General</h3><p>In clinical trials, the most common side effects reported with emtricitabine and tenofovir alafenamide (with elvitegravir and cobicistat) were nausea, diarrhea, and headache.</p><p></p><p>Side effects have been reported for emtricitabine and/or tenofovir disoproxil fumarate (DF) when taken in combination with other antiretroviral agents.  The most common side effects reported in HIV-1-infected patients during a clinical study of efavirenz, emtricitabine, and tenofovir DF included diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash.  In this trial, emtricitabine-tenofovir DF (with efavirenz) was used from weeks 96 to 144, replacing emtricitabine plus tenofovir DF (with efavirenz).</p><p></p><p>In HIV-1-uninfected individuals in HIV-1 preexposure prophylaxis trials, the most common side effect reported with emtricitabine-tenofovir alafenamide was diarrhea while the most common side effects reported with emtricitabine-tenofovir DF were headache, abdominal pain, and decreased weight.<sup>[Ref]</sup></p><h3>Other</h3><p>Emtricitabine-tenofovir alafenamide:</p><p>-Common (1% to 10%): Fatigue</p><p>-Frequency not reported: Decreased high-density lipoprotein (HDL) cholesterol (fasted), increased triglycerides (fasted), increased total cholesterol to HDL ratio</p><p></p><p>Emtricitabine-tenofovir DF:</p><p>-Very common (10% or more): Increased fasting cholesterol (up to 22%)</p><p>-Common (1% to 10%): Fatigue, syphilis, secondary syphilis, decreased phosphorus, increased fasting triglycerides, weight decreased, increased alkaline phosphatase</p><p>-Frequency not reported: Decreased total cholesterol (fasted), decreased HDL cholesterol (fasted), decreased low-density lipoprotein (LDL) cholesterol (fasted), decreased triglycerides (fasted), increased total cholesterol to HDL ratio</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Common (1% to 10%): Fatigue, increased fasting total cholesterol, increased fasting LDL cholesterol</p><p>-Frequency not reported: Increased HDL cholesterol, increased triglycerides</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Asthenia</p><p>-Common (1% to 10%): Pain</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Pain, asthenia, increased triglycerides</p><p>-Common (1% to 10%): Chest pain, fever, weight loss</p><p>-Frequency not reported: Higher 1,25 vitamin D levels</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Increased weight, increased blood lipid levels<sup>[Ref]</sup></p><p>Increased fasting cholesterol (greater than 240 mg/dL: up to 22%), decreased phosphorus (2.5 to less than the lower limit of normal: up to 7%; less than 2 mg/dL: up to 10%), increased fasting triglycerides (greater than 750 mg/dL: up to 5%), and increased alkaline phosphatase (greater than 550 units/L: 1%) have been reported with emtricitabine-tenofovir DF.</p><p></p><p>In clinical trials, the following mean increases were reported in antiretroviral therapy-naive patients after using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat for 48 weeks: total cholesterol increased by 30 mg/dL, LDL cholesterol by 15 mg/dL, HDL cholesterol by 7 mg/dL, triglycerides by 29 mg/dL.  In clinical trials, the following mean increases were reported in patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat for 96 weeks: fasted total cholesterol increased by 31 and 14 mg/dL, fasted LDL cholesterol by 18 and 7 mg/dL, fasted HDL cholesterol by 7 and 4 mg/dL, fasted triglycerides by 31 and 13 mg/dL.</p><p></p><p>Increased fasting LDL cholesterol (greater than 190 mg/dL) has been reported in 8% and 4% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.  Increased fasting total cholesterol (greater than 300 mg/dL) has been reported in 3% and 2% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p><p></p><p>Asthenia has also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Emtricitabine-tenofovir DF:</p><p>-Very common (10% or more): Increased AST (up to 14%), increased ALT (up to 14%)</p><p>-Frequency not reported: Severe acute exacerbations of hepatitis B</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Common (1% to 10%): Increased AST</p><p></p><p>Emtricitabine:</p><p>-Common (1% to 10%): Increased serum AST and/or increased serum ALT, hyperbilirubinemia</p><p>-Frequency not reported: Liver failure, liver decompensation, severe hepatomegaly with steatosis</p><p></p><p>Tenofovir DF:</p><p>-Common (1% to 10%): Increased transaminases (AST and/or ALT)</p><p>-Rare (less than 0.1%): Hepatic steatosis, hepatitis</p><p>-Frequency not reported: Severe hepatomegaly with steatosis</p><p>-Postmarketing reports: Increased liver enzymes (primarily AST, ALT, GGT)<sup>[Ref]</sup></p><p>Increased AST (1.25 to less than 2.5 times the upper limit of normal [1.25 to less than 2.5 x ULN]: up to 14%; greater than 2.6 x ULN: up to 5%) and ALT (1.25 to less than 2.5 x ULN: up to 14%; greater than 2.6 x ULN: up to 7%) have been reported with emtricitabine-tenofovir DF.</p><p></p><p>Increased AST (greater than 180 units/L) and ALT (greater than 215 units/L) have been reported in 3% and 2% of males using emtricitabine-tenofovir DF, respectively.  Increased AST (greater than 170 units/L) and ALT (greater than 170 units/L) have been reported in 3% and 2% of females using emtricitabine-tenofovir DF, respectively.</p><p></p><p>Increased AST (greater than 5 x ULN) has been reported in 2% and 2% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p><p></p><p>Severe acute exacerbations of hepatitis have been reported in patients with hepatitis B after discontinuation of this drug and were associated with liver failure and liver decompensation in some emtricitabine-treated patients.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p><p></p><p>Hepatic steatosis and hepatitis have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Decreased neutrophils (1000 to 1300/mm3: up to 13%; less than 750/mm3: up to 5%) and hemoglobin (8.5 to 10 mg/dL: 4%; less than 9.4 mg/dL: up to 2%) have been reported with emtricitabine-tenofovir DF.</p><p></p><p>Anemia was common in pediatric patients using emtricitabine.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir DF:</p><p>-Very common (10% or more): Decreased neutrophils (up to 13%)</p><p>-Common (1% to 10%): Decreased hemoglobin</p><p></p><p>Emtricitabine:</p><p>-Common (1% to 10%): Neutropenia</p><p>-Uncommon (0.1% to 1%): Anemia</p><p></p><p>Tenofovir DF:</p><p>-Common (1% to 10%): Decreased neutrophils<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Emtricitabine-tenofovir DF:</p><p>-Very common (10% or more): Pharyngitis (up to 13%)</p><p>-Common (1% to 10%): Sinusitis, upper respiratory tract infections, nasopharyngitis</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Rhinitis, increased cough</p><p></p><p>Tenofovir DF:</p><p>-Common (1% to 10%): Pneumonia</p><p>-Postmarketing reports: Dyspnea<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Increased serum amylase (greater than 175 units/L) has been reported in up to 8% of patients using emtricitabine-tenofovir DF.</p><p></p><p>In clinical trials, nausea was the most common side effect reported in antiretroviral therapy-naive HIV-1-infected patients using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat.</p><p></p><p>Increased amylase (greater than 2 x ULN) has been reported in 2% and 4% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p><p></p><p>Pancreatitis, abdominal pain, and increased amylase have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir alafenamide:</p><p>-Common (1% to 10%): Diarrhea, nausea, abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal discomfort)</p><p></p><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Diarrhea, nausea, increased serum amylase, abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, gastrointestinal pain, abdominal discomfort), vomiting</p><p>-Frequency not reported: Flatulence</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Very common (10% or more): Nausea</p><p>-Common (1% to 10%): Diarrhea, vomiting, abdominal pain, flatulence, increased amylase</p><p>-Uncommon (0.1% to 1%): Dyspepsia</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Diarrhea, nausea, abdominal pain</p><p>-Common (1% to 10%): Increased amylase (including increased pancreatic amylase), increased serum lipase, vomiting, dyspepsia</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Diarrhea, vomiting, nausea</p><p>-Common (1% to 10%): Abdominal pain, abdominal distension, flatulence, dyspepsia, increased serum amylase</p><p>-Uncommon (0.1% to 1%): Pancreatitis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>In clinical trials of HIV-1-uninfected individuals, decreased BMD was reported.  During treatment with emtricitabine-tenofovir DF, 13% of patients lost at least 5% of BMD at the spine.</p><p></p><p>Increased creatine kinase (males: greater than 990 units/L; females: greater than 845 units/L) has been reported in up to 9% of patients using emtricitabine-tenofovir DF.</p><p></p><p>Increased creatine kinase (at least 10 x ULN) has been reported in 9% and 7% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p><p></p><p>In virologically-suppressed tenofovir DF-treated patients who switched to emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean BMD increased between baseline and week 48; decreased BMD was also reported.</p><p></p><p>Rhabdomyolysis, osteomalacia, muscular weakness, and myopathy may occur as a result of proximal renal tubulopathy.</p><p></p><p>Rhabdomyolysis, muscular weakness, and myopathy have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir alafenamide:</p><p>-Common (1% to 10%): Decreased bone mineral density (BMD)</p><p>-Frequency not reported: Increased BMD</p><p></p><p>Emtricitabine-tenofovir DF:</p><p>-Very common (10% or more): Decreased BMD</p><p>-Common (1% to 10%): Increased creatine kinase, bone fractures, back pain</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Very common (10% or more): Decreased BMD</p><p>-Common (1% to 10%): Increased creatine kinase</p><p>-Uncommon (0.1% to 1%): Arthralgia</p><p>-Frequency not reported: Increased biochemical markers of bone metabolism, increased BMD, fractures (excluding fingers and toes)</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Increased creatine kinase</p><p>-Common (1% to 10%): Myalgia, arthralgia</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Increased creatine kinase</p><p>-Common (1% to 10%): Myalgia, arthralgia, back pain</p><p>-Uncommon (0.1% to 1%): Rhabdomyolysis, muscular weakness</p><p>-Rare (less than 0.1%): Myopathy</p><p>-Frequency not reported: Decreased BMD, increased biochemical markers of bone metabolism</p><p>-Postmarketing reports: Osteomalacia (manifested as bone pain and which may contribute to fractures)</p><p></p><p>Combination antiretroviral therapy:</p><p>-Frequency not reported: Osteonecrosis<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Hyperglycemia (greater than 250 mg/dL) has been reported in up to 2% of patients using emtricitabine-tenofovir DF.</p><p></p><p>Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.</p><p></p><p>Hypokalemia and hypophosphatemia may occur as a result of proximal renal tubulopathy.</p><p></p><p>Hypokalemia, lactic acidosis, and hypophosphatemia have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Hyperglycemia</p><p></p><p>Emtricitabine:</p><p>-Common (1% to 10%): Hyperglycemia, hypertriglyceridemia, increased or decreased serum glucose</p><p>-Frequency not reported: Lactic acidosis</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Hypophosphatemia</p><p>-Common (1% to 10%): Anorexia, increased serum glucose</p><p>-Uncommon (0.1% to 1%): Hypokalemia</p><p>-Rare (less than 0.1%): Lactic acidosis</p><p></p><p>Antiretroviral therapy:</p><p>-Frequency not reported: Redistribution of body fat (lipodystrophy), increased glucose levels<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Depression, insomnia, abnormal dreams, anxiety</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Common (1% to 10%): Abnormal dreams</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Insomnia, abnormal dreams</p><p>-Common (1% to 10%): Depressive disorders</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Depression</p><p>-Common (1% to 10%): Insomnia, anxiety<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Emtricitabine-tenofovir alafenamide:</p><p>-Common (1% to 10%): Headache</p><p></p><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Dizziness, headache</p><p>-Frequency not reported: Somnolence</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Common (1% to 10%): Headache, dizziness</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Dizziness, headache</p><p>-Common (1% to 10%): Neuropathy/peripheral neuritis, paresthesia</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Dizziness, headache</p><p>-Common (1% to 10%): Peripheral neuropathy (including neuropathy, peripheral neuritis)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Rash event (including rash, maculopapular rash, exfoliative rash, generalized rash, macular rash, pruritic rash, vesicular rash)</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Common (1% to 10%): Rash</p><p>-Uncommon (0.1% to 1%): Pruritus</p><p></p><p>Emtricitabine:</p><p>-Very common (10% or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash, allergic reaction)</p><p>-Common (1% to 10%): Skin discoloration (palmar-plantar hyperpigmentation)</p><p>-Frequency not reported: Lipodystrophy</p><p>-Postmarketing reports: Angioedema</p><p></p><p>Tenofovir alafenamide-containing products:</p><p>-Postmarketing reports: Angioedema, urticaria, rash</p><p></p><p>Tenofovir DF:</p><p>-Very common (10% or more): Rash event (including rash, pruritus, maculopapular rash, urticaria, vesiculobullous rash, pustular rash)</p><p>-Common (1% to 10%): Sweating</p><p>-Uncommon (0.1% to 1%): Lipodystrophy</p><p>-Rare (less than 0.1%): Angioedema<sup>[Ref]</sup></p><p>Skin discoloration (hyperpigmentation) was very common in pediatric patients using emtricitabine.</p><p></p><p>Rash has also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Renal</h3><p>Increased creatinine (1.1 to 1.3 x ULN: up to 2%; greater than 1.4 x ULN: less than 1%) has been reported with emtricitabine-tenofovir DF.</p><p></p><p>In 2 trials in antiretroviral therapy-naive HIV-1-infected patients (median estimated glomerular filtration rate [eGFR] 115 mL/min at baseline) using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine increased by 0.1 mg/dL from baseline to week 48; median UPCR was 44 mg/g at baseline and at week 48.  In a trial in virologically-suppressed tenofovir DF-treated patients (mean eGFR 112 mL/min at baseline) who switched to emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine was similar to baseline; median UPCR was 61 mg/g at baseline and 46 mg/g at week 48.  In a trial in renal dysfunction patients (baseline eGFR 30 to 69 mL/min) using emtricitabine plus tenofovir alafenamide with elvitegravir plus cobicistat, mean serum creatinine was 1.5 mg/dL at baseline and week 24; median UPCR was 161 mg/g at baseline and 93 mg/g at week 24.</p><p></p><p>Proximal renal tubulopathy generally resolved or improved after tenofovir DF was stopped; however, decreased CrCl did not completely resolve in some HIV-1-infected patients after stopping the drug.  Rhabdomyolysis, osteomalacia, bone abnormalities (infrequently contributing to fractures), hypokalemia, muscular weakness, myopathy, and hypophosphatemia may occur as a result of proximal renal tubulopathy.</p><p></p><p>Renal failure, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, increased creatinine, nephrogenic diabetes insipidus, and acute tubular necrosis have also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><p>Emtricitabine-tenofovir alafenamide:</p><p>-Uncommon (0.1% to 1%): Increased urine protein-to-creatinine ratio (UPCR)</p><p>-Frequency not reported: Decreased serum creatinine, increased estimated glomerular filtration rate (eGFR)</p><p></p><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Increased creatinine, increased UPCR</p><p>-Frequency not reported: Decreased eGFR</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Frequency not reported: Increased serum creatinine, decreased UPCR, worsening renal function</p><p></p><p>Tenofovir DF:</p><p>-Uncommon (0.1% to 1%): Increased creatinine, proximal renal tubulopathy (including Fanconi syndrome)</p><p>-Rare (less than 0.1%): Renal failure (acute and chronic), acute tubular necrosis, nephrogenic diabetes insipidus</p><p>-Frequency not reported: New onset or worsening renal impairment</p><p>-Postmarketing reports: Renal insufficiency, interstitial nephritis (including acute cases)</p><p></p><p>Tenofovir prodrugs:</p><p>-Frequency not reported: Renal impairment (including renal failure, Fanconi syndrome)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p>Emtricitabine-tenofovir DF:</p><p>-Common (1% to 10%): Proteinuria, urethritis, urinary tract infection, hematuria, genital ulceration, anogenital warts</p><p>-Uncommon (0.1% to 1%): Glycosuria</p><p></p><p>Emtricitabine plus tenofovir alafenamide:</p><p>-Common (1% to 10%): Hematuria</p><p></p><p>Tenofovir DF:</p><p>-Common (1% to 10%): Glycosuria, hematuria</p><p>-Uncommon (0.1% to 1%): Proteinuria</p><p>-Postmarketing reports: Polyuria<sup>[Ref]</sup></p><p>Hematuria (greater than 75 RBC/high power field: up to 3%) and glycosuria (3+ or greater: less than 1%) have been reported with emtricitabine-tenofovir DF.</p><p></p><p>Hematuria (greater than 75 RBC/high power field) has been reported in 3% and 3% of patients using emtricitabine plus tenofovir alafenamide and emtricitabine plus tenofovir DF, respectively, each with elvitegravir plus cobicistat.</p><p></p><p>Proteinuria has also been reported during postmarketing experience with tenofovir DF.<sup>[Ref]</sup></p><h3>Immunologic</h3><p>Emtricitabine-tenofovir DF:</p><p>-Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)</p><h3>Hypersensitivity</h3><p>Emtricitabine:</p><p>-Common (1% to 10%): Allergic reaction</p><p></p><p>Tenofovir DF:</p><p>-Postmarketing reports: Allergic reaction (including angioedema)<sup>[Ref]</sup></p><h3>Endocrine</h3><p>Tenofovir DF:</p><p>-Frequency not reported: Higher serum parathyroid hormone levels<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Truvada (emtricitabine-tenofovir)." Gilead Sciences, Foster City, CA. </p><p id="ref_4">4. "Product Information. Descovy (emtricitabine-tenofovir)." Gilead Sciences, Foster City, CA. </p><p id="ref_5">5. Panel on Antiretroviral Guidelines for Adults and Adolescents "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Available from: URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf."   ([2018, May 30]):</p><p id="ref_6">6. Baeten JM,  Donnell D,  Ndase P, et al. "Antiretroviral prophylaxis for HIV prevention in heterosexual men and women." N Engl J Med 367 (2012): 399-410</p><p id="ref_7">7. Piacenti FJ "An update and review of antiretroviral therapy." Pharmacotherapy 26 (2006): 1111-33</p><p id="ref_8">8. Paxton LA,  Hope T,  Jaffe HW "Pre-exposure prophylaxis for HIV infection: what if it works?" Lancet 370 (2007): 89-93</p><p id="ref_9">9. de Perio MA,  Gomez FJ,  Frame PT,  Fichtenbaum CJ "A truvada hypersensitivity reaction simulating abacavir hypersensitivity." AIDS 21 (2007): 2252-3</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Truvada vs Descovy: How do they compare for HIV and PrEP?</li>
</ul><h2>More about AccessPak for HIV PEP Basic (emtricitabine / tenofovir)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>1 Review</li>
<li>Drug class: antiviral combinations</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>HIV Infection</li>
<li>Nonoccupational Exposure</li>
<li>Occupational Exposure</li>
<li>Pre-Exposure Prophylaxis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>